Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 6/2003

01-06-2003 | Author's Reply

DQ-LTR13 modifies Type 1 diabetes (IDDM) susceptibility on high risk DQ haplotypes: reply to the comments of Pascual et al.

Authors: K. Krach, M. A. Pani, C. Seidl, J. Van Autreve, B. J. Van der Auwera, F. K. Gorus, R. R. Tönjes, Dr. K. Badenhoop

Published in: Diabetologia | Issue 6/2003

Login to get access

Excerpt

To the Editor: Although we refer to Pascual's study in our original paper [1], these authors like to reiterate their earlier conclusion that DQ-LTR13 is not associated with "autoimmunity" [2]. However the two studies are completely different and therefore not comparable. …
Literature
1.
Bieda K, Pani MA, Van der Auwera B (2002) A retroviral long terminal repeat adjacent to the HLA DQB1 gene (DQ-LTR13) modifies Type I diabetes susceptibility on high risk DQ haplotypes. Diabetologia 45:443–447CrossRef
2.
Pascual M, Martin J, Nieto A et al. (2001) Distribution of HERV-LTR elements in the 5′-flanking region of HLA-DQB1 and association with autoimmunity. Immunogenetics 53:114–118CrossRefPubMed
3.
Donner H, Tonjes RR, Bontrop RE et al. (1999) Intronic sequence motifs of HLA-DQB1 are shared between humans, apes and Old World monkeys, but a retroviral LTR element (DQLTR3) is human specific. Tissue Antigens 53:551–558CrossRefPubMed
4.
Donner H, Tonjes RR, Van der Auwera B et al. (1999) The presence or absence of a retroviral long terminal repeat influences the genetic risk for type 1 diabetes conferred by human leukocyte antigen DQ haplotypes. J Clin Endocrinol Metab 84:1404–1408
5.
Seidl C, Donner H, Petershofen E et al. (1999) An endogenous retroviral long terminal repeat at the HLA-DQB1 gene locus confers susceptibility to rheumatoid arthritis. Hum Immunol 60:63–68CrossRefPubMed
6.
Donner H, Tönjes RR, Bontrop RE, Kurth R, Usadel KH, Badenhoop K (2000) MHC diversity in Caucasians, investigated using highly heterogeneous noncoding sequence motifs at the DQB1 locus including a retroviral long terminal repeat element, and its comparison to nonhuman primate homologues. Immunogenetics 51:898–904PubMed
7.
Pani MA, Seidl C, Bieda K et al. (2002) Preliminary evidence that an endogenous retroviral long terminal repeat (LTR13) at the HLA-DQB1 gene locus confers susceptibility to Addison's disease. Clin Endocrinol (Oxf) 56:773–777
Metadata
Title
DQ-LTR13 modifies Type 1 diabetes (IDDM) susceptibility on high risk DQ haplotypes: reply to the comments of Pascual et al.
Authors
K. Krach
M. A. Pani
C. Seidl
J. Van Autreve
B. J. Van der Auwera
F. K. Gorus
R. R. Tönjes
Dr. K. Badenhoop
Publication date
01-06-2003
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 6/2003
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-003-1114-8

Other articles of this Issue 6/2003

Diabetologia 6/2003 Go to the issue

Article

Atopic eczema in early childhood could be protective against Type 1 diabetes

Article

Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-β1 and fibronectin expression in mesangial cells

Article

Homocysteine as a risk factor for nephropathy and retinopathy in Type 2 diabetes

Article

Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis

Short Communication

Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1

Short Communication

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits